Article info
PDFOriginal research
Practical allocation system for the distribution of specialised care during cellular therapy access scarcity
- Correspondence to Dr Andrew Hantel, Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago IL 60637, USA; ahantel{at}medicine.bsd.uchicago.edu
Citation
Practical allocation system for the distribution of specialised care during cellular therapy access scarcity
Publication history
- Received December 30, 2018
- Revised April 5, 2019
- Accepted April 27, 2019
- First published June 19, 2019.
Online issue publication
August 27, 2019
Article Versions
- Previous version (19 June 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
- Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
- Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma